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• We examine whether variation in gonadotropin signaling pathway genes is associated with ovarian cancer risk.
• We evaluate individual SNP effects and gene-level effects through burden testing using the admixture likelihood (AML) method.
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Objective. Ovarian cancer is a hormone-related disease with a strong genetic basis. However, none of its
high-penetrance susceptibility genes and GWAS-identiﬁed variants to date are known to be involved in
hormonal pathways. Given the hypothesized etiologic role of gonadotropins, an assessment of how variability
in genes involved in the gonadotropin signaling pathway impacts disease risk is warranted.
Methods. Genetic data from 41 ovarian cancer study sites were pooled and unconditional logistic regression
was used to evaluate whether any of the 2185 SNPs from 11 gonadotropin signaling pathway genes was
associated with ovarian cancer risk. A burden test using the admixture likelihood (AML) method was also used
to evaluate gene-level associations.
Results.We did not ﬁnd any genome-wide signiﬁcant associations between individual SNPs and ovarian cancer
risk. However, there was some suggestion of gene-level associations for four gonadotropin signaling pathway
genes: INHBB (p=0.045,mucinous), LHCGR (p=0.046, high-grade serous),GNRH (p=0.041, high-grade serous),
and FSHB (p = 0.036, overall invasive). There was also suggestive evidence for INHA (p = 0.060, overall invasive).
Conclusions. Ovarian cancer studies have limited sample numbers, thus fewer genome-wide susceptibility
alleles, with only modest associations, have been identiﬁed relative to breast and prostate cancers. We have evalu-
ated the majority of ovarian cancer studies with biological samples, to our knowledge, leaving no opportunity for
replication. Using both our understanding of biology and powerful gene-level tests, we have identiﬁed four putative
ovarian cancer loci near INHBB, LHCGR,GNRH, and FSHB thatwarrant a second look if larger sample sizes and denser
genotype chips become available.© 2014 Elsevier Inc. All rights reserved.Introduction
Invasive epithelial ovarian cancer (ovarian cancer) is a hormone-
related cancer with oral contraceptive (OC) use and parity as well-
established protective factors [1]. Long-standing hormonal hypotheses
include incessant ovulation, direct effects of estrogen and progesterone,
and gonadotropin signaling [2–4]. The gonadotropin hypothesis
suggests that ovarian cancer develops from excess stimulation of ovari-
an tissue by the pituitary gonadotropins, follicle stimulating hormone
(FSH) and luteinizing hormone (LH), whose secretion is controlled by
the gonadotropin releasing hormone (GnRH) [4].
Ovarian cancer also has a signiﬁcant heritable component in which a
ﬁrst-degree family history of ovarian cancer is associatedwith an approx-
imate two-fold increased risk [5]. This risk may be attributable to high-
penetrance susceptibility genetic mutations as well as several common
variants that have been identiﬁed through genome-wide association
studies (GWAS) [6–13]. It was widely expected that genes involved in
hormone signaling and action would be associated with ovarian cancer
risk, but none of the GWAS-identiﬁed variants or major genes appears
to be involved in hormonal pathways. Conversely, in other cancers affect-
ed byhormones, such as breast cancer, hormone-related genetic variation
was associated with disease risk [14]. However, a substantial portion of
ovarian cancer's excess familial risk still remains unexplained.
Detailed analyses of gene-level effects of genes involved in gonado-
tropin signaling have not been undertaken. Three population-based
case–control studies have assessed the effects of genetic variants in
the FSH receptor gene (FSHR), but with conﬂicting results [15–17].
Hence, we have carried out a comprehensive multi-center analysis to
determinewhether genetic variation in 11 genes involved in the gonad-
otropin signaling pathway is associated with ovarian cancer risk.
Methods
This study was approved by the ethics committees of each institu-
tion. Each subject provided written informed consent prior to inclusion
in the study.Study populations
In total, 41 study sites from the Ovarian Cancer Association
Consortium (OCAC), which constituted 31 study sets, have been includ-
ed in this analysis; study siteswere grouped into sets based on the scope
of genotyping data (genome-wide versus targeted approaches) as well
as the geographic region. Brieﬂy, 20 study sites were conducted in
Europe, 19 in North America, and two in Australia. Nine study sites
were case-only so their cases were pooled with case–control study
sites from the same geographic region. In addition, the three Polish
case–control study sites were combined into a single study set. An over-
view of each site's characteristics and number of cases and controls are
presented in Supplementary Table S1. Our analyses excluded partici-
pants who were not of European ancestry (n = 4605), as determined
by the program LAMP (Local Ancestry in Admixed Populations) (see
“Statistical analysis”), or were missing ethnicity information (n = 23).
In addition, only invasive epithelial ovarian cancer cases were
considered. Hence, a combined total of 46,176 participants (n =
15,361 cases and 30,815 controls) was used in our ﬁnal analyses. De-
tails regarding sample quality control have been published
previously [9].Imputation analyses
These analyses were based on genotype data from three GWAS and
replication efforts [8,18] as well as the large-scale genotyping array by
the Collaborative Oncological Gene-environment Study (COGS) [12].
Details of these large-scale genotyping efforts have been published
previously.
To account for different marker sets and improve genome coverage,
imputation of the entire scope of genetic variation in the genome was
carried out by combining the available genotyped data as well as infor-
mation from theMarch 2012 release of the 1000 Genomes Project using
the program IMPUTE2 [19]. The data were pre-phased using SHAPEIT
software to reduce computation time [20].
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Eleven gonadotropin signaling pathway geneswere evaluated in our
analyses: ACVR1, ACVR2, CGA, FSHB, FSHR, GNRH, GNRHR, INHA, INHBA,
INHBB, and LHCGR. SNPs found within each gene as well as SNPs within
25 kbupstreamanddownstreamof each genewere assessed. Only SNPs
with an imputation r2 ≥ 0.5 and a minor allele frequency (MAF) ≥ 0.05
were considered in the analyses. Hence, our ﬁnal analyses included
2185 SNPs.
Statistical analysis
The program LAMP was used to assign intercontinental ancestry
based on genotype frequencies in European, Asian, and African popula-
tions [21]. Participants with 90% or more European ancestry were
classiﬁed as European. To adjust for ancestry within the European
population, a principal components analysis (PCA) was performed
within our subjects using a set of 37,000 unlinked markers as well as
an in-house program written in C++ that used the Intel MKL library
for eigenvectors (http://ccge.medschl.cam.ac.uk/software/pccalc).
Coverage referred to the total proportion of genetic variation being
captured for each gene at an r2 ≥ 0.8. It was determined by calculating
the pairwise r2 between the SNPs we had genotypes for (with an impu-
tation r2 ≥ 0.5 and a MAF ≥ 0.05) and all of the 1000 Genomes SNPs in
each gene that had a MAF ≥ 0.05.
Unconditional logistic regression was used to assess the association
between each SNP in the gonadotropin signaling pathway genes and
ovarian cancer risk. All analyses took into consideration study set and
adjusted for population substructure by including the ﬁrst ﬁve PCA
eigenvalues in the model. This was done for all invasive ovarian cancer
as well as for the four ovarian cancer histological subtypes (high-grade
serous, mucinous, endometrioid, clear cell). Per-allele log odds ratios
(ORs) and 95% conﬁdence intervals (CIs) were estimated. All reported
p-values were two-sided.
Because wewere interested in identifyingwhether or not individual
genes (versus the individual SNPs) were associatedwith ovarian cancer
risk, a burden testwas performed using the admixture likelihood (AML)
method [22] to determine whether overall genetic variation in each
gonadotropin signaling gene was associated with disease risk after
accounting for the correlation between the SNPs in each gene.
The AML method postulates that within a set of SNPs, a given
proportion α is associated with the outcome, and the effect size of
each associated SNP will fall on a non-central χ2 distribution with
non-centrality parameter η. The η parameter is a measure closely relat-
ed to that SNP's contribution to the genetic variance of the outcome var-
iable. The AML method estimates values for α and η using a pseudo-
maximum likelihood method. Due to a lack of independence among
our SNPs, it is not possible to assess the signiﬁcance of the estimated pa-
rameters by a simple likelihood ratio test so the AML method was used
to assess signiﬁcance by simulation instead.
We used the AMLcalc program (http://ccge.medschl.cam.ac.uk/
software/aml) to perform the burden test using 1000 simulations with
themaximumproportion of associated SNPs set to 0.2 on the genotyped
and imputed data and adjusting for the ﬁrst ﬁve ancestry principal
components. p-Values for the AML trend test are provided.
Results
The number of SNPs analyzed for each gene and the number of SNPs
statistically signiﬁcantly associatedwith invasive ovarian cancer risk (at
a nominal p ≤ 0.05 signiﬁcance level) are presented in Table 1. Neither
GNRH nor GNRHR harbored a SNP associated with overall invasive ovar-
ian cancer at the p ≤ 0.05 level (Table 1). LHCGR had the most strongly
associated single SNP, rs72618637 (p = 0.001; Table 1), but FSHB
showed some evidence of a gene-level association (p = 0.036;
Table 1). A borderline statistically signiﬁcant gene-level associationbetween INHA and invasive ovarian cancer was also observed (p =
0.060). However, when all SNPs across the 11 genes were considered
together (“global”), no evidence of an association between genetic
variation in the gonadotropin signaling pathway and invasive ovarian
cancer risk was observed (p = 0.33).
Results of the most signiﬁcant association for each gene by histolog-
ical subtype are presented in Tables 2A and 2B. FSHB had the most
strongly associated single SNP, rs7951733 (p = 4.62 × 10−5; Table 2B
and Supplementary Fig. S1) across all histological subtypes, including
overall invasive, and also showed suggestive evidence of a gene-level
association with the invasive endometrioid subtype (p= 0.063). In ad-
dition, while genetic variation across the 11 genes did not show evi-
dence of a global association with any of the four histological
subtypes, there was evidence of gene-level associations between
LHCGR and GNRH and the invasive high-grade serous subtype (p =
0.046 and p=0.041, respectively) aswell as between INHBB and the in-
vasive mucinous subtype (p= 0.045). However, there was no evidence
of any gene-level association with the invasive clear cell subtype.
Discussion
The gonadotropin hypothesis has been one of the leading hypothe-
ses concerning ovarian cancer development. After evaluating this path-
way,we found individual SNP associations at the p≤ 0.05 level, which is
intriguing, but none was statistically signiﬁcant after considerations for
multiple comparisons. Rs7951733, which was an imputed SNP in our
dataset (r2 = 0.95) with a MAF = 0.08, was particularly interesting
given its strong association with the endometrioid ovarian cancer sub-
type (p = 4.62 × 10−5, Supplementary Fig. S1). It is located approxi-
mately 5 kb downstream of the FSHB gene, which encodes the beta
polypeptide of FSH, a gonadotropin involved in reproduction. However,
the relevance of this SNP remains uncertain.
In this case where many nominally signiﬁcant associations were
observed, an alternative method for evaluating whether variation in
this pathway is associated with risk is needed. A standard approach
would be to attempt replication. However, to our knowledge, our anal-
ysis includes the majority of ovarian cancer cases and controls available
worldwide for genetic studies. Hence, we conducted burden testing
using the AML approach to evaluate evidence of gene-level associations.
This method did provide some evidence of gene-level associations. A
total of 55 burden testswere carried out (i.e., 11 genes × 5 types of ovar-
ian cancer (overall invasive plus the four subtypes of ovarian cancer)),
in which four signiﬁcant associations (FSHB, LHCGR, GNRH, and INHBB)
and one borderline signiﬁcant association (INHA) were observed, com-
pared to 2.8 expected by chance at the p≤ 0.05 level. This lends support
to a possible role for genetic variation in this pathwaywith ovarian can-
cer risk.
Given that most ovarian cancer patients present at a postmenopaus-
al stage when circulating FSH and LH levels are high and remain high
due to the lack of negative feedback mechanisms by ovarian steroids,
an association between chronically elevated gonadotropin levels and
ovarian carcinogenesis has been suggested [23]. This is further support-
ed by elevated gonadotropin levels in cyst and peritoneal ﬂuid from
ovarian cancer patients, although their relevance when the carcinogen-
esis has already occurred is uncertain [24]. Epidemiological evidence in-
directly supporting the role of gonadotropins in ovarian carcinogenesis
includes the well-established protective effects of pregnancies and OC
use, which suppress gonadotropin secretion by the pituitary gland
[25]. The gonadotropin hypothesis has also prompted substantial
work on the potential risk-enhancing effects of infertility treatments,
which include high-doses of gonadotropins to induce ovulation [26].
Hence, while gonadotropins alone may not reconcile all of the data
pertaining to ovarian cancer etiology and progression, the evidence sug-
gests that they are at least partly involved; it has been hypothesized that
high gonadotropin levels could stimulate ovarian epithelial cells and
initiate or promote tumorigenesis.
Table 1
Gene-level AML test and most signiﬁcantly associated SNP (MAFa ≥ 0.05) in each gonadotropin signaling gene for all invasive ovarian cancers.
Gene Coverage
(at imputation r2 ≥ 0.8)
Number of
SNPs
Number of signiﬁcant
SNPs (at ≤0.05)
AML burden
testb
Most signiﬁcant
SNP
MAFa Imputation
r2
ORc p-Value
ACVR1 0.55 101 1 0.73 rs35160507 0.07 0.77 1.07 0.030
ACVR2 0.98 163 1 0.52 rs17742573 0.07 0.56 0.93 0.046
CGA 0.97 140 15 0.29 rs7745823 0.24 0.83 0.96 0.035
FSHB 0.99 111 18 0.036 rs12805742 0.22 0.94 1.04 0.018
FSHR 0.90 746 15 0.57 chr2:49204261:D 0.07 0.70 0.91 0.007
GNRH 1.00 108 0 0.65 N/A – – – –
GNRHR 0.94 126 0 0.59 N/A – – – –
INHA 0.86 81 15 0.060 rs12720063 0.21 1.00 0.95 0.007
INHBA 1.00 77 1 0.80 rs17776182 0.15 1.00 0.95 0.010
INHBB 0.82 109 22 0.098 rs11900747 0.06 0.55 1.13 0.004
LHCGR 0.97 423 52 0.091 rs72618637 0.19 0.68 1.07 0.001
Global – 2185 140 0.33 – – – – –
Note: “N/A” reﬂects genes with no signiﬁcant SNPs at p ≤ 0.05. “Global” refers to when all genes are considered.
a MAF =minor allele frequency.
b AML = admixture maximum likelihood, taking into account the ﬁrst ﬁve ancestry principal components; p-values for trend reported.
c OR= per allele odds ratio, taking into account study set and the ﬁrst ﬁve ancestry principal components.
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rs6166) may affect susceptibility of women to ovarian cancer [15–17].
However, the results from three studies that investigated this were
conﬂicting. Our analysis of 746 SNPs in this gene included these two
variants, but neither was found to be associated with risk of ovarian
cancer (p = 0.46 and p = 0.45, respectively).
Our results suggest that theremay be other genes involved in the go-
nadotropin signaling pathway that might affect risk of developing ovar-
ian cancer and speciﬁc subtypes of ovarian cancer as well. In addition,
the molecular function of such genes makes their involvement in ovar-
ian carcinogenesis biologically plausible. GNRH is predominantly re-
sponsible for the release of the pituitary gonadotropins, FSH and LH,
whichmakes it a likely gene to be involved in this pathway. INHBB or in-
hibin beta B is a subunit of inhibin, which is produced by the granulosa
cells of the ovary and has been found to be a possible marker of ovarian
cancer [27]. The potential association we report with the mucinous
ovarian cancer subtype is interesting given case reports describing a
combination of granulosa cell tumor and mucinous cystadenoma of
the ovary [28,29]. It joins the alpha subunit of inhibin (INHA) to form
a pituitary FSH secretion inhibitor. LHCGR or luteinizing hormone/
choriogonadotropin receptor produces a protein that acts as a receptor
for two ligands: LH, which plays a role in ovulation, and chorionic
gonadotropin, which is necessary for pregnancy. In addition, evidence
suggests an association between genetic variability in LHCGR and risk
of ovarian hyperstimulation syndrome [30]. FSHB encodes the beta
polypeptide of FSH, which has long been thought to play a role inTable 2A
Gene-level AML test and most signiﬁcantly associated SNP (MAFa ≥ 0.05) in each gonadotropi
Gene Coverage
(at r2 ≥ 0.8)
Serous high grade (n = 6258)
No. of
signif.
SNPs
AML
burden
testb
Most signiﬁcant
SNP
MAFa Imput.
r2
ORc
ACVR1 0.55 0 0.47 N/A – – –
ACVR2 0.98 1 0.66 rs57870939 0.05 0.60 1.13
CGA 0.97 0 0.69 N/A – – –
FSHB 0.99 1 0.35 rs7925340 0.21 0.99 1.05
FSHR 0.90 31 0.52 rs116044731 0.07 0.80 0.87
GNRH 1.00 12 0.041 chr8:25283745:D 0.42 0.62 1.07
GNRHR 0.94 0 0.34 N/A – – –
INHA 0.86 5 0.24 rs77120825 0.06 0.51 1.16
INHBA 1.00 2 0.52 rs17719440 0.08 0.98 1.11
INHBB 0.82 12 0.15 rs4328642 0.05 0.58 0.86
LHCGR 0.97 90 0.046 rs13426172 0.12 1.00 0.91
Global – 154 0.24 – – – –
Note: “N/A” reﬂects genes with no signiﬁcant SNPs at p ≤ 0.05. “Global” refers to when all gen
a MAF =minor allele frequency.
b AML = admixture maximum likelihood, taking into account the ﬁrst ﬁve ancestry princip
c OR= per allele odds ratio, taking into account study set and the ﬁrst ﬁve ancestry principovarian carcinogenesis due to well-established protective factors that
suppress its secretion [25].
Despite three genome-wide scans andmultiple large-scale genotyp-
ing efforts, only 18 genome-wide signiﬁcant ovarian cancer susceptibil-
ity alleles have been identiﬁed, compared to 76 in breast and 77 in
prostate [unpublished results, 31]. This is largely attributable to limited
sample numbers available in each study, which emphasizes the impor-
tance of collaborative efforts, such as OCAC. In addition, because of
limited numbers, new statistical methods are needed to better
understand the role of genetics in ovarian cancer etiology. This study
highlights one such method. By linking biology with burden testing,
we were able to ﬁnd some evidence of an association between the go-
nadotropin signaling genes GNRH, INHBB, FSHB, and LHCGR and ovarian
cancer risk.
None of the individual SNP associations we observed showed
genome-wide signiﬁcance (p = 5 × 10−8) and are thus circumstantial.
However, we applied burden testing to evaluate gene-level effects as
well, and although this does not allow us to identify the speciﬁc
disease-associated variant, it does shed some light on potential genes
to focus on in future studies. In addition, although much of the genetic
data used were imputed, we restricted our analyses to only SNPs with
an imputation r2 ≥ 0.5 and a MAF ≥ 0.05, which is a common method
used for ﬁltering imputed data [32].
While these ﬁndings cannot be directly applied to a clinical setting,
they demonstrate both a biological and genetic basis to the role of
gonadotropins in ovarian carcinogenesis, which could impact hown signaling gene for invasive high-grade serous and mucinous ovarian cancers.
Mucinous (n = 991)
p-Value No. of
signif.
SNPs
AML
burden
testb
Most signiﬁcant
SNP
MAFa Imput.
r2
ORc p-Value
– 1 0.76 rs17804523 0.07 0.67 0.79 0.042
0.038 6 0.38 rs11681013 0.08 0.74 1.23 0.025
– 1 0.50 chr6:87820107:I 0.29 0.89 1.11 0.039
0.049 37 0.11 rs12577729 0.22 0.95 1.14 0.018
0.003 45 0.33 rs12997920 0.39 0.88 1.13 0.010
0.010 0 0.40 N/A – – – –
– 0 0.78 N/A – – – –
0.013 0 0.43 N/A – – – –
0.008 0 0.55 N/A – – – –
0.010 26 0.045 rs6542591 0.39 0.67 1.17 0.003
0.005 21 0.67 rs55871926 0.10 0.80 1.26 0.004
– 137 0.54 – – – – –
es are considered.
al components; p-values for trend reported.
al components.
Table 2B
Gene-level AML test and most signiﬁcantly associated SNP (MAFa ≥ 0.05) in each gonadotropin signaling gene for invasive endometrioid and clear cell ovarian cancers.
Gene Coverage
(at r2 ≥ 0.8)
Endometrioid (n = 2148) Clear cell (n = 1013)
No. of
signif.
SNPs
AML
burden
testb
Most signiﬁcant
SNP
MAFa Imput.
r2
ORc p-Value No. of
signif.
SNPs
AML
burden
testb
Most signiﬁcant
SNP
MAFa Imput.
r2
ORc p-Value
ACVR1 0.55 2 0.47 chr2:158719453:D 0.06 0.85 1.14 0.042 0 0.87 N/A – – – –
ACVR2 0.98 1 0.25 rs17742573 0.07 0.56 0.84 0.045 12 0.21 rs55816333 0.42 0.97 0.89 0.018
CGA 0.97 0 0.95 N/A – – – – 0 0.58 N/A – – – –
FSHB 0.99 27 0.063 rs7951733 0.08 0.95 0.76 4.62 × 10−5 0 0.46 N/A – – – –
FSHR 0.90 19 0.34 rs191446440 0.05 0.62 1.30 0.002 45 0.20 rs55926033 0.12 0.87 1.21 0.007
GNRH 1.00 0 0.13 N/A – – – – 1 0.35 chr8:25290793:D 0.09 0.55 1.23 0.038
GNRHR 0.94 2 0.53 rs148964181 0.13 0.55 1.12 0.045 3 0.31 rs17637021 0.17 0.52 1.18 0.026
INHA 0.86 3 0.14 rs6436158 0.40 0.52 0.91 0.042 0 0.86 N/A – – – –
INHBA 1.00 0 0.58 N/A – – – – 0 0.94 N/A – – – –
INHBB 0.82 15 0.16 rs12475606 0.47 0.55 0.90 0.016 2 0.70 rs4528762 0.26 0.60 0.81 0.003
LHCGR 0.97 8 0.65 rs4293599 0.20 1.00 1.12 0.005 9 0.69 rs3884614 0.07 0.66 1.29 0.005
Global – 77 0.33 – – – – – 72 0.53 – – – – –
Note: “N/A” reﬂects genes with no signiﬁcant SNPs at p ≤ 0.05. “Global” refers to when all genes are considered.
a MAF =minor allele frequency.
b AML = admixture maximum likelihood, taking into account the ﬁrst ﬁve ancestry principal components; p-values for trend reported.
c OR= per allele odds ratio, taking into account study set and the ﬁrst ﬁve ancestry principal components.
547A.W. Lee et al. / Gynecologic Oncology 136 (2015) 542–548researchers and clinicians viewovarian cancer etiology. Based on our re-
sults, the gonadotropin hypothesis would be worth re-evaluating when
larger samples with denser genotyping chips become available so that
there is more power with less reliance on imputation, allowing for
ﬁne mapping to be carried out.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2014.12.017.
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